Fig. 3From: Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumabKaplan–Meier 24-months curves of overall survival (OS; a) and progression-free survival (PFS; b) of metastatic melanoma patients treated with nivolumab, according to basal sCD73 enzyme activity. Blue line: CD73 <27.8 pmol/min/mg protein; green line: CD73 >27.8 pmol/min/mg proteinBack to article page